Phase II study to begin for an adjunctive therapy for multiple sclerosis

Stuart SchlossmanMS Research Study and Reports

Information provide by Thomas Mann

Transparency Life Sciences
December 27, 2012
We are pleased to announce that the US Food and Drug
Administration (FDA) last week cleared our Investigational New Drug
Application (IND) to assess lisinopril as an adjunctive therapy for
multiple sclerosis (MS), giving us the safety approval necessary to proceed
with a Phase II study. You can read more about our lisinopril IND here: IND Press Release.
Our lisinopril protocol made extensive use of input from a crowd
of researchers and patients. If you participated by completing a Protocol
Builder™ for MS, we want to extend a special word of thanks.  In
keeping with our commitment to full data transparency, we have placed the lisinopril protocol on our website for
your comments and suggestions.
 
Thank you for your participation, and have a happy new year.
 
Tomasz Sablinski, MD, PhD
Co-founder and CEO
Transparency Life Sciences, LLC 
 

..

If you would like, you can comment to our blog posts
 LIKE this Blog by clicking the LIKE button – top left
 REMAIN up to date with MS News and Education
Visit: www.msviewsandnews.org  to register
.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews